Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $314.6MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17 '26 | Option Exercise | $115.67 | 15,000 | $1,735,050 | 209,451 | Aug 18 06:31 PM |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17 '26 | Sale | $263.36 | 15,000 | $3,950,400 | 194,451 | Aug 18 06:31 PM |
| Taubert Jennifer L | Officer | Aug 17 '26 | Proposed Sale | $263.36 | 15,000 | $3,950,418 | — | Aug 17 12:51 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.